Functional avoidance-based intensity modulated proton therapy with 4DCT derived ventilation imaging for lung cancer

Jingjing M. Dougherty | Edward Castillo | Richard Castillo | Austin M. Faught | Mark Pepin | Sean S. Park | Chris J. Beltran | Thomas Guerrero | Inga Grills | Yevgeniy Vinogradskiy

Abstract

The primary objective is to evaluate the potential dosimetric gains of performing functional avoidance-based proton treatment planning using 4DCT derived ventilation imaging. 4DCT data of 31 patients from a prospective functional avoidance clinical trial were evaluated with intensity modulated proton therapy (IMPT) plans and compared with clinical volumetric modulated arc therapy (VMAT) plans. Dosimetric parameters were compared between standard and functional plans with IMPT and VMAT with one-way analysis of variance and post hoc paired student t-test. Normal Tissue Complication Probability (NTCP) models were employed to estimate the risk of two toxicity endpoints for healthy lung tissues. Dose degradation due to proton motion interplay effect was evaluated. Functional IMPT plans led to significant dose reduction to functional lung structures when compared with functional VMAT without significant dose increase to Organ at Risk (OAR) structures. When interplay effect is considered, no significant dose degradation was observed for the OARs or the clinical target volume (CTV) volumes for functional IMPT. Using fV20 as the dose metric and Grade 2+ pneumonitis as toxicity endpoint, there is a mean 5.7% reduction in Grade 2+ RP with the functional IMPT and as high as 26% in reduction for individual patient when compared to the standard IMPT planning. Functional IMPT was able to spare healthy lung tissue to avoid excess dose to normal structures while maintaining satisfying target coverage. NTCP calculation also shows that the risk of pulmonary complications can be further reduced with functional based IMPT.

KEY WORDS

4DCT, functional lung imaging, IMPT, lung toxicity, lung ventilation, proton motion interplay, proton therapy, radiation pneumonitis
1 | INTRODUCTION

1.A | Functional avoidance radiation therapy for definitive lung cancer

The regional function heterogeneity of lung tissues has long been exploited in the design of external beam radiation therapy treatment planning using single photon emission tomography (SPECT) with radiopharmaceutical aerosols. Positron emission tomography (PET) paired with a positron emitting inert gas is another reported ventilation imaging method. Hyperpolarized xenon or helium magnetic resonance imaging (MRI) techniques have also been reported to generate pulmonary ventilation information. With the advent of 4DCT-based pulmonary ventilation calculation, the changes in the local air content are converted into pulmonary functional images to guide the placing and optimization of radiation treatment beams. Currently, there are multiple National Institutes of Health (NIH) funded clinical trials (NCT02528942, NCT02308709, and NCT02843568) that aim to investigate the efficacy of the functional avoidance-based treatment planning techniques.

1.B | Proton beam therapy for lung cancer

The ability of proton beams to stop in tissue within a finite range provides its dosimetric superiority over conventional external beam photon therapy. However, complexity in proton treatment planning increases when considering uncertainties in proton range, patient daily setup, physiological changes of the tumor, CT density conversion, and tumor motion. In a recent large-cohort retrospective comparison study, the National Cancer Database was queried to analyze the outcomes and predictors associated with proton therapy for stage I-IV non-small cell lung cancer (NSCLC) patients; better 5-year overall survival was reported for proton radiation therapy; better overall survival rates and tolerable toxicities were also reported for stage II-III NSCLC when using proton therapy with concurrent chemotherapy. More clinical trials are available to investigate the effect of proton beam therapy on local control rates, toxicity, and survival improvement for patients with early or advanced stage lung cancer (NCT00875901, NCT01629498, NCT01993810, NCT03132532).

With more proton centers employing scanning pencil beam methods for treatment delivery and plan optimization, the interplay effect of tumor motion and proton spot arrangement has gone through vigorous numerical simulations, measurement validations, and methods to manage it have been clinically implemented. The layer or volumetric dose repainting techniques are the most investigated and applied methodologies in mitigating dose degradation caused by the motion interplay effect due to relatively easy clinical implementation within commercial treatment planning systems.

The purpose of this study is to investigate the potential dosimetric gains and toxicity reduction for the 4DCT-based functional avoidance treatment planning technique using robustly optimized intensity modulated proton therapy (IMPT). Clinical data from a phase II photon functional avoidance study were exported to perform an in-silico comparison with functional based proton planning using a structural-based approach. We report the dosimetric comparison and estimate the reduction in radiation pneumonitis toxicity using a prior published Normal Tissue Complication Probability (NTCP) model developed directly from clinical plans and the dose values to the high functioning lungs.

2 | METHODS AND MATERIALS

2.A | Patient characteristics and selection

This study was approved by the institutional review boards at University of Colorado, Denver (IRB #14-1586) and Beaumont Health System (IRB #2016-037). All patients included in the study provided written informed consent. The cohort included 31 patients who have stage I-IV or recurrent SCLC and NSCLC treated with definitive radiation therapy (45–60 Gy). Table 1 presents the patient characteristics. The primary patient selection criterion was the presence of a significant ventilation defect based on the lung functional profile obtained through 4DCT imaging. Quantitatively, we divided each lung into superior, middle, and inferior regions and calculated the percent ventilation in each third of the lung. If a patient’s ventilation image showed a reduction of 15% or more in ventilation in any one of the lung regions, the patient was deemed eligible for functional based planning. All 31 patients included in this study had significant ventilation defects. Patients with homogenous lung function were excluded from the study. The maximal tumor amplitude was evaluated in MIM (MIM Software Inc., Cleveland, OH) using deformable image registration of the GTV contours from the 4DCT data. For irregularly shaped or large tumor volume, only the portion of the GTV with the largest motion amplitude was reported.

2.B | 4DCT-based ventilation calculation

The phase-resolved pre-treatment 4DCT simulation data from each patient was used to generate the pulmonary ventilation. Lung parenchyma was first segmented from the trachea, main bronchi, pulmonary vasculature, and the gross tumor volume on both the peak inhale and peak exhal phase data using intensity-based segmentation algorithm. This segmented lung tissue mask determined the spatial domain in the inhale and exhale CT data where pulmonary ventilation was quantified. Based on the method proposed by Simon, the fractional changes in air content due to pulmonary ventilation in a specific CT voxel was represented by

$$\frac{V_{in} - V_{ex}}{V_{ex}} = \frac{1000 \times \frac{HU_{in} - HU_{ex}}{HU_{ex}(1000 + HU_{in})}}{1000 \times \frac{HU_{in} - HU_{ex}}{HU_{ex}(1000 + HU_{in})}}.$$  \hspace{1cm}(1)$$

where $V_{in}$ and $V_{ex}$ are the volumes of air within the inhale and exhal CT voxel pair respectively, and $HU_{in}$ and $HU_{ex}$ are the Hounsfield units of the mapped voxel pairs corresponding to the inhale and exhale breathing phases. Prior to the ventilation calculation, an intensity-based quadratic penalty deformable image registration algorithm, with a spatial accuracy of 1.2 mm, was applied to establish spatial correspondence between the inhale and the exhale HU values.
The CT Hounsfield unit based ventilation calculation method, represented by eq. (1) was applied to each exhale CT voxel within the lung mask. The result was a 3D distribution of the normalized fractional change in voxel air content co-registered to the peak exhale phase data. Figure 1 shows an example of the pulmonary ventilation generated using this workflow. According to eq. (1), for a given voxel in the exhale state, a fractional ventilation value of 0 means no change in volume between inhale and exhale. Such a voxel might be fixed in position with no displacement or they might only possess translational motion with no deformation between breathing states. A value of 1.0 means the initial volume has doubled going from exhale to inhale. The color scale map in Fig. 1 has the range of the RGB color spectrum from dark blue (value = 0) to red (value = max). The color scale is normalized to the maximum volume change and represented in percentage.

2.C | 4DCT-based functional avoidance treatment planning with volumetric modulated arc therapy (VMAT)

Although there are different methods for functional based treatment planning reported in the literature, this study employed the structural based treatment planning technique. In practice, a functional lung structure was auto-segmented from the ventilation images by using a lower intensity threshold of 15%, which was normalized to the patient global maximum pixel intensity value. This functioning lung structure was further modified into different optimization structures to constrain the planning objectives for functional planning, while the standard planning does not consider functional structures. The photon data consisted of a standard lung plan and a clinically treated functional avoidance plan. Because the clinical trial involves two institutions, some of the patients were planned using the Varian Eclipse (Varian, Palo Alto, CA) treatment planning software with a True Beam machine and the rest of the VMAT plans were generated with the Pinnacle (Philips Healthcare) treatment planning system using an Elekta Agility (Elekta, Stockholm, Sweden). The gross tumor volume (GTV) was identified with contrast enhanced CT and/or PET scans. The internal gross tumor volume (iGTV) was designed to include the GTV motion in all phases of the 4DCT. The clinical target volume (CTV) was generated from an isotropic expansion of the iGTV by 6–10 mm. The planning target volume (PTV) was created by a 5 mm uniform expansion of the CTV. The planning constraints for the PTV and normal tissue structures generally followed the Radiation Therapy Oncology Group (RTOG) 0617 for NSCLC and RTOG 0538 for SCLC.

| Characteristics | Value or no. of patients |
|-----------------|--------------------------|
| Median age at diagnosis | 64 (44–81) |
| Diagnosis |  |
| SCLC | 5 |
| NSCLC | 26 |
| Stage |  |
| IA | 1 |
| IIA | 3 |
| IIIB | 4 |
| IV | 4 |
| Gender |  |
| Female | 20 |
| Male | 11 |
| Mean prescribed dose, Gy (RBE) (range) |  |
| SCLC | 48 (45–60) |
| NSCLC | 58.2 (50–60) |
| Tumor location |  |
| LUL | 8 |
| LLL | 5 |
| RUL | 12 |
| RML | 2 |
| RLL | 4 |
| Median max. tumor motion, cm (range) | 0.6 (0.2–2.1) |

Abbreviations: LUL, left upper lobe; LLL, left lower lobe; NSCLC, non-small cell lung cancer; RBE, relative biological effectiveness; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; SCLC, small cell lung cancer.
standardize the functional planning process between institutions, the planners were instructed to prioritize (1) Planning Target Volume (PTV) coverage, (2) meeting Organ at Risk (OAR) constraints, and (3) reducing dose to the functional lung structures.

2.D | 4DCT-based functional avoidance treatment planning with IMPT

The standard IMPT plans and functional avoidance IMPT plans were generated using the multi-field optimization (MFO) method in the Eclipse Treatment Planning system v15.1 (Varian, Palo Alto, CA) with a 2.5 × 2.5 × 2.5 mm³ dose grid size and with two to three treatment fields per plan. A Hitachi Probeat-V proton therapy system with 97 discrete proton energy levels were modeled and used for planning. This clinical machine model consists of a spot library with sigma in air (at isocenter) ranging from 5.7 mm at the lowest energy 71.3 MeV, to 2.5 mm at the highest energy 228.8 MeV, at the isocenter. In order to mitigate the dose degradation due to the interplay effect, a max MU iso-layer spot repainting version of the machine model was used for planning. Instead of additional margin expansion from the CTV, range and setup errors were explicitly considered as part of the optimization problem to ensure robust CTV.

| TABLE 2 | The comparison of DVH dose metrics between standard and functional treatment plans (n = 31) are presented for both VMAT and IMPT |
|-------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Volumetric Arc Therapy | Standard plan—Mean (SD) | Functional Plan—Mean (SD) | P value | Intensity Modulated Proton | Standard plan—Mean (SD) | Functional Plan—Mean (SD) | P value |
| CTV metrics | | | | | | | |
| CTV max (RBE[Gy]) | 70.93 (16) | 71.45 (15.9) | 0.1 | 62.09 (5.9) | 62.86 (5.9) | 0.001* |
| Conformity index | 2.22 (0.7) | 2.15 (0.7) | 0.002* | 1.79 (0.4) | 1.71 (0.4) | 0.001* |
| Homogeneity index | 1.22 (0.3) | 1.23 (0.3) | 0.02 | 1.10 (0.2) | 1.11 (0.2) | 0.001* |
| OAR Metrics | | | | | | | |
| Total MLD (RBE[Gy]) | 16.14 (2.7) | 15.28 (2.9) | <0.001* | 9.73 (3.3) | 8.78 (2.9) | <0.001* |
| Total lung V20 (%) | 27.57 (5.7) | 25.50 (6.1) | <0.001* | 19.54 (6.8) | 17.06 (5.7) | <0.001* |
| Total lung V5 (%) | 66.8 (11.2) | 64.89 (12.9) | 0.005 | 29.80 (9.2) | 27.67 (8.5) | <0.001* |
| Esophagus mean (RBE[Gy]) | 24.79 (8.2) | 24.10 (8.6) | 0.005 | 19.57 (10.0) | 19.56 (10.1) | 0.92 |
| Heart mean (RBE[Gy]) | 11.90 (6.2) | 11.88 (6.4) | 0.92 | 4.62 (2.9) | 4.77 (3.5) | 0.75 |
| Cord max (RBE[Gy]) | 36.18 (8.4) | 36.72 (8.4) | 0.46 | 31.84 (9.9) | 33.57 (8.8) | 0.1 |
| Functional lung metrics | | | | | | | |
| Ipsilateral | | | | | | | |
| MLD (RBE[Gy]) | 24.38 (7.2) | 22.49 (7.0) | <0.001* | 17.65 (7.6) | 14.72 (6.7) | <0.001* |
| Lung fV5 (%) | 77.9 (17.6) | 76.5 (18.3) | 0.005 | 53.81 (18.2) | 48.10 (17.9) | <0.001* |
| Lung fV20 (%) | 51.6 (17.1) | 45.57 (16.9) | <0.001* | 35.83 (16.2) | 28.05 (13.7) | <0.001* |
| Lung fV30 (%) | 34.9 (16.1) | 30.75 (14.8) | <0.001* | 26.70 (14.2) | 21.25 (12) | <0.001* |
| Contralateral | | | | | | | |
| MLD (RBE[Gy]) | 9.26 (3) | 7.99 (2.7) | <0.001* | 1.75 (2.4) | 1.66 (2.2) | 0.74 |
| Lung fV5 (%) | 69.6 (14.2) | 66.08 (15.3) | 0.015 | 8.24 (11.1) | 6.88 (8.9) | 0.002* |
| Lung fV20 (%) | 5.79 (6.6) | 4.10 (5.5) | <0.001* | 2.68 (4.7) | 1.66 (3.1) | 0.004 |
| Lung fV30 (%) | 1.68 (3) | 1.34(2.6) | 0.013 | 1.02 (2.3) | 0.75 (1.7) | 0.015 |
| Total lung | | | | | | | |
| MLD (RBE[Gy]) | 16.05 (3.3) | 14.49 (3.3) | <0.001* | 8.82 (3.9) | 7.31 (3.3) | <0.001* |
| Lung fV5 (%) | 73.7 (11.5) | 71.06 (13.3) | 0.003 | 28.78 (11.6) | 25.40 (10.3) | <0.001* |
| Lung fV10 (%) | 52.8 (13.7) | 43.92 (12.8) | <0.001* | 24.47 (10.4) | 20.20 (8.4) | <0.001* |
| Lung fV20 (%) | 26.38 (8.3) | 22.66 (8.2) | <0.001* | 17.59 (8.4) | 13.48 (6.6) | <0.001* |
| Lung fV30 (%) | 16.31 (6.9) | 14.30 (6.6) | <0.001* | 12.49 (6.9) | 9.89 (5.7) | <0.001* |
| Lung fV40 (%) | 10.54 (6.0) | 9.28 (5.7) | <0.001* | 7.32 (4.9) | 5.78 (4.1) | <0.001* |
| Lung fV50 (%) | 5.95 (4.2) | 5.44 (4.2) | 0.006 | 5.78 (4.1) | 4.82 (3.6) | <0.001* |

Note: Functional lung metrics: Using the auto-segmented functional lung structures from the calculated ventilation map. CTV = iGTV + Margin (Margin = 6 to 10 mm).

Abbreviations: fVX (%), functional %volume that receives X Gy; MLD, mean lung dose; OAR, organ at risk; RBE, relative biological effectiveness.

aStatistically significant P value with multiple testing corrected alpha level 0.002.
Robust proton plans were created with the Eclipse NUPO robust optimization algorithm. A setup uncertainty of 5 mm and a range uncertainty of 5% were chosen as the robust optimization parameters to account for patient daily setup errors and proton range uncertainties. During the plan robustness evaluation, for both the standard and functional avoidance plans, 95% of the CTV was required to be covered by 95% of the prescription dose in the worst-case robustness scenario. If any of the worst-case scenario plans didn’t fulfill this clinical goal, the IMPT plan was re-optimized with higher weighting on the CTV target coverage objectives to increase the plan robustness. As part of the routine plan check and quality assurance process, the proton plans have been re-calculated using an in-house GPU accelerated Monte Carlo 2nd check dose engine.

2.E | Proton 4D interplay effect simulation

In order to estimate the 4D dynamic dose, an in-house 4D simulation program was used to incorporate experimentally validated synchrotron proton spot scanning timing parameters and a GPU accelerated Monte Carlo dose calculation engine. The in-house MC dose engine was benchmarked against GEANT4 simulations. The standard deviation of the disagreement of the models was found to be around 1% after accounting for the statistical uncertainties of both Monte Carlo techniques. The evaluation was carried out on a subset of the functional IMPT plans, selected based on tumor size and motion amplitude. Seven patients were chosen from the study cohort. The median and maximum tumor motion were 0.6 cm and 2.1 cm. Based on tumor motion, the patients chosen for simulation has a representative range of the following motion amplitudes: 0.4 cm, 0.7 cm, 0.8 cm, 0.9 cm, 1.4 cm, 1.7 cm, and 2.1 cm. Also, patients were chosen based on their tumor volumes, the smallest tumor size was 108 cc and the largest tumor size was 834 cc. Proton dose was simulated and re-calculated using this 4D dynamic dose pipeline to evaluate dose degradation caused by the interplay effect. The differences between the nominal Monte Carlo dose and the 4D dynamic dose for the following metrics were determined: $D_{99}\%$, $D_{95}\%$, and $D_{95}\%$ of the CTV volumes, mean lung dose, mean esophagus dose, max cord dose, V20% and V30% of the functional lung, and the mean functional lung dose. A total of 6 simulations were performed for each patient by selecting 2 different breathing start phases (max inhale and max exhale) in combination with 3 different breathing periods (3, 5, and 7 s).

2.F | Dosimetric comparison and statistical analysis

A number of the CTV volume and organ at risk (OAR) dose metrics were evaluated for the comparison of the standard and functional VMAT and IMPT plans (see Table 2). For comparison reasons, the standard and functional IMPT plans, and the standard and functional VMAT plans, were all normalized to D99 of the CTV receiving 99% of the prescription. Comparison of the means of the dosimetric parameters was performed with the one-way analysis of variance (ANOVA) with 0.05 selected as the alpha level. Post-hoc paired student t-tests with multiple testing correction were used to determine which groups demonstrated a difference in means.

2.G | Pulmonary toxicity analysis with functional lung NTCP model

Faught et al. reported a functional lung NTCP model that shows strong predictive capacity for Grade 2+ and Grade 3+ radiation pneumonitis (RP), using the fractional volume of functional lung receiving 20 Gy, 30 Gy, and the mean functional lung dose (fDV20 Gy, fDV30 Gy, and fMLD). In an effort to quantify the possible toxicity reduction from 4DCT-based functional avoidance plans, we applied their NTCP model and the dose metrics of the functional lung volumes to estimate the toxicity probability of the mean and its associated absolute reduction in Grade 2+ and Grade 3+ RP toxicity for both the photon and proton plans.
3 RESULTS

3.A Dose statistics comparison between IMPT and VMAT

Figure 2 illustrates the isodose distribution of the standard and functional plans with VMAT and IMPT for one representative patient. The yellow arrows indicate where the most functional sparing occurred, given the sets of beam angles and optimization objectives used for this patient. Table 2 shows the mean and standard deviation of the dosimetric parameters as well as the $P$ values for the corresponding $t$ test. There are no significant dose differences observed for the esophagus, heart, and spinal cord between the standard and functional plans when comparing the same treatment modality. The functional IMPT plans show significant dose reduction when compared to the functional VMAT plans for the MLD at 15.28 Gy vs. 8.78 Gy, the lung $V_{20}$ at 25.5% vs. 17.06%, mean esophagus dose at 24.1 Gy vs. 19.56 Gy, mean heart dose at 11.88 Gy vs. 4.77 Gy, cord max dose at 36.72 Gy vs. 33.57 Gy, fMLD at 14.49 Gy vs. 7.31 Gy, f$V_{20}$ at 22.66% vs. 13.48%, and...
Degradation was observed for the CTV D95% from 17.59% (8.4%) to 13.48% (6.6%). Gy, the fV10 from 28.78% (11.6%) to 25.4% (10.3%), and the fV20 from 14.3% vs. 9.9%. When comparing the standard IMPT and the functional IMPT plans, the functional IMPT plans showed significant functional sparing to the fMLD from 8.82 (3.9) Gy to 7.31 (3.3) Gy, the fV10 from 28.78% (11.6%) to 25.4% (10.3%), and the fV20 from 17.59% (8.4%) to 13.48% (6.6%).

3.B | Interplay effect analysis on functional IMPT plans

Figure 3 shows the DVH metric differences between the nominal Monte Carlo plans and the 4D dynamic plans. No significant dose difference was observed for the D95c–D95% and D95% of the CTV volumes, mean lung dose, mean esophagus dose, max cord dose, V20% and V30% of the functional lung, as well as the mean functional lung dose. As a general observation, as the motion amplitude increases, there is increasing differences in the functional V20% and V30% of the lung, as well as the functional mean lung dose. The maximum observed difference in CTV D95c–D95% metric between the nominal plan and the 4D dynamic plan was 2.2 Gy. No significant dose degradation was observed for the CTV D95%.

3.C | Pulmonary toxicity reduction

Table 3 shows the estimated mean NTCP for Grade 2+ RP on three of the functional dose metrics and the calculated absolute toxicity reduction between functional and standard plans. There was statistically significant difference between the standard and the functional plans. An absolute reduction of 1.8%, 3.3%, and 5.7% was observed for fMLD, fV30, and fV20 dose metrics. For a certain patient, as high as 26% in absolute reduction was observed in Grade 2+ RP when planning with functional IMPT. We also report the Grade 3+ RP NTCP calculation results in Table A1 as an additional reference.

4 | DISCUSSION

The results presented in this study support the feasibility and the potential dosimetric gains of 4DCT-derived functional avoidance IMPT planning for lung patients. By utilizing functional lung structures as additional optimization objectives, dose to the functional lung structures can be reduced without significant dose increases to the OAR structure. In contrast to the proton planning study performed by Huang et al.,44 we selected patient data from a prospective lung functional avoidance clinical trial with significant functional defects. We did not observe significant OAR dose increase when generating functional IMPT plans. We have also investigated the potential dose degradation caused by the scanning proton beam interplay effects.

It should be pointed out that one of the participating institutions (with 23 patients enrolled) permits dose escalation to the GTV with a 115% hotspot relative to the PTV dose. For some patients, the global maximum point dose could be as high as 130% of the PTV prescription. The IMPT plans were further generated by two different methods. The first method allowed the hot spot to exceed 130% of the prescription, while the second method required the strict adherence to our clinical proton lung treatment planning standard of practice (SOP), where the hot spot could not exceed 110%. Because of the differences in planning practice between institutions and modalities, we first performed dose metrics comparison of the OAR and functional lung structures as additional optimization objectives, dose to the functional lung structures can be reduced without significant dose increases to the OAR structure. In contrast to the proton planning study performed by Huang et al., we selected patient data from a prospective lung functional avoidance clinical trial with significant functional defects. We did not observe significant OAR dose increase when generating functional IMPT plans. We have also investigated the potential dose degradation caused by the scanning proton beam interplay effects.

Recently, a consensus statement has been published by the Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee,42 recommending that active motion management techniques, breath holding, beam gating, repainting, tracking, or adaptive planning should be used when significant motion (>5–10 mm) or

| Grade 2+ Toxicity | Dose metric for NTCP | Toxicity probability of the mean (range)—VMAT standard | Toxicity probability of the mean (range)—VMAT functional | Absolute reduction (range) |
|-------------------|---------------------|---------------------------------------------------------|--------------------------------------------------------|--------------------------|
| fV20 Gy           | 31.3% (5.9%–67.8%)  | 25.1% (5.5%–60.2%)                                     | 6.2% (–0.1%–13.1%)                                      |
| fV30 Gy           | 24.5% (9%–50.1%)    | 21.5% (8.5%–45.8%)                                     | 3% (0.1%–7.4%)                                         |
| fV20 Gy           | 24.1% (11.9%–33.4%) | 21.8% (11.4%–31.5%)                                     | 2.3% (–0.1%–5.5%)                                      |
| Dose metric for NTCP | Toxicity probability of the mean (range)—IMPT Standard | Toxicity probability of the mean (range)—IMPT Functional | Absolute Reduction (Range) |
| fV20 Gy           | 17.6% (4.4%–51.3%)  | 12.7% (3.9%–36.1%)                                     | 5.70% (0%–26%)                                         |
| fV30 Gy           | 19% (7.9%–47.5%)    | 15.7% (7.3%–35.9%)                                     | 3.30% (0%–15.3%)                                       |
| fV20 Gy           | 14.6% (7.7%–25.4%)  | 12.9% (7.4%–21.3%)                                     | 1.80% (0%–5.9%)                                        |
| fV30 Gy           | 24.1% (9%–50.1%)    | 21.5% (8.5%–45.8%)                                     | 3% (0.1%–7.4%)                                         |
| fV20 Gy           | 24.1% (11.9%–33.4%) | 21.8% (11.4%–31.5%)                                     | 2.3% (–0.1%–5.5%)                                      |

Table 3 shows the estimated mean NTCP for Grade 2+ radiation pneumonitis are shown here for the average functional lung volume metrics for the standard and functional plans with both the VMAT and IMPT methods.
changes in motion or anatomy occurs during treatments. Clinically, a number of these techniques are currently being utilized in our department to decrease the motion interplay effect in proton patients. The severity of the proton dose degradation caused by the interplay effect depends largely on proton therapy system parameters, such as the spot size, scanning magnet speed, dose rate, as well as the breathing amplitude, tumor size, and breathing regularity of a patient during treatment. Our 4D dynamic dose simulation showed that functional based IMPT plans were still robust against motion interplay for selected patients. Practical motion management strategies can be applied clinically for functional guided IMPT treatments. One shortcoming of our simulation on the interplay effect is that only one 4D dynamic dose simulation was performed for each patient data. Since it is generally believed that the dose interplay effect will be smeared out or lessened when we increase the number of treatment fractions. We believe our simulations will provide the worst-case scenario where the entire prescription dose was delivered as a single fraction. However, the accuracy of the simulation still requires experimental validation with dosimetric measurements.

Additional analysis was also performed to investigate whether the amount of functional volume reduction was correlated to tumor volume or tumor location; unfortunately, there was no indication that the functional lung metrics correlates with tumor volume and location. Another important point is that the functional IMPT plans require the functional structures to be robustly spared. In other words, during the optimization of the IMPT plans, the functional lung structures must have no significant dose increase in the worst-case scenario plans; the plan robustness curves or the robustness DVH band should be tightly grouped for the CTV volume, as well as for the functional lung structures. We would also like to point out that the NTCP functional model was generated with photon clinical lung plans and may not be entirely accurate for proton lung plans in estimating still requires experimental validation with dosimetric measurements.

CONFLICT OF INTEREST

No conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

1. Alderson PO, Line BR. Scintigraphic evaluation of regional pulmonary ventilation. Semin Nucl Med. 1980;10:218–242.
2. Burch WM, Sullivan PJ, McLaren CJ. Technegas—a new ventilation agent for lung scanning. Nucl Med Commun. 1986;7:865–871.
3. Suga K. Technical and analytical advances in pulmonary ventilation SPECT with xenon-133 gas and Tc-99m-Technegas. Ann Nucl Med. 2002;16:303–310.
4. Valind SO, Rhodes CG, Brudin LH, Jones T. Measurements of regional ventilation pulmonary gas volume: theory and error analysis with special reference to positron emission tomography. J Nucl Med. 1991;32:1937–1944.
5. Wellman TJ, Winkler T, Costa EL, et al Measurement of regional specific lung volume change using respiratory-gated PET of inhaled 13N-nitrogen. J Nucl Med. 2010;51:646–653.
6. Albert MS, Cates GD, Driehuys B, et al Biological magnetic resonance imaging using laser-polarized 129Xe. Nature. 1994;370:199–201.
7. Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV. Noninvasive assessment of regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nat Med. 1996;2:1236–1239.
8. Yablonisky DA, Sukstanskii AL, Quirk JD, Woods JC, Conradi MS. Probing lung microstructure with hyperpolarized noble gas diffusion MRI: theoretical models and experimental results. Magn Reson Med. 2014;71:486–505.
9. Guerrero T, Sanders K, Noyola-Martinez J, et al Quantification of regional ventilation from treatment planning CT. Int J Radiat Oncol Biol Phys. 2005;62:630–634.
10. Simon BA. Non-invasive imaging of regional lung function using x-ray computed tomography. J Clin Monit Comput. 2000;16:433–442.
11. Vinogradskiy Y, Castillo R, Castillo E, et al Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. Int J Radiat Oncol Biol Phys. 2013;86:366–371.
12. Vinogradskiy Y, Faught A, Castillo R, et al Using 4D-ventilation to characterize lung function changes for pediatric patients getting thoracic radiotherapy. J Appl Clin Med Phys. 2018;19:407–412.
13. Vinogradskiy Y, Rushhoven CG, Schubert L, et al Interim analysis of a two-institution, prospective clinical trial of 4D-ventilation-based functional avoidance radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102:1357–1365.
14. Vinogradskiy Y, Schubert L, Dlot Q, et al Regional lung function profiles of stage I and III lung cancer patients: an evaluation for functional avoidance radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:1273–1280.
15. Higgins KA, O’Connell K, Liu Y, et al National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97:128–137.
16. Elhammali A, Blanchard P, Yoder A, et al Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019;136:136–142.
17. Hoppe BS, Henderson R, Pham D, et al A phase 2 trial of concurrent chemotherapy and proton therapy for stage III non-small cell lung cancer: results and reflections following early closure of a single-institution study. *Int J Radiat Oncol Biol Phys*. 2016;95:517–522.

18. Nguyen Q-N, Ly NB, Komaki R, et al Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II–III inoperable non-small cell lung cancer. *Radiother Oncol*. 2015;115:367–372.

19. Dowdell S, Grassberger C, Sharp GC, Paganetti H. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. *Phys Med Biol*. 2013;58:4137–4156.

20. Grassberger C, Dowdell S, Lomax A, et al Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancer. *Int J Radiat Oncol Biol Phys*. 2013;86:380–386.

21. Kraus KM, Heath E, Oelfke U. Dosimetric consequences of tumour motion due to respiration for a scanned proton beam. *Phys Med Biol*. 2011;56:6563–6581.

22. Lambert J, Suchowierska N, McKenzie DR, Jackson M. Intrafractional motion during proton beam scanning. *Phys Med Biol*. 2005;50:4853–4862.

23. Seco J, Robertson D, Trofmov A, Paganetti H. Breathing interplay effects during proton beam scanning: simulation and statistical analysis. *Phys Med Biol*. 2009;54:N283–294.

24. Krieger M, Klimpi G, Fattori G, et al Experimental validation of a deforming grid 4D dose calculation for PBS proton therapy. *Phys Med Biol*. 2018;63:055005.

25. Ribeiro CO, Knopf A, Langendijk JA, Weber DC, Lomax AJ, Zhang Y. Assessment of dosimetric errors induced by deformable image registration methods in 4D pencil beam scanned proton treatment planning for liver tumours. *Radiother Oncol*. 2018;128:174–181.

26. Kardar L, Li Y, Li X, et al Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. *Pract Radiat Oncol*. 2014;4:e259–e268.

27. Knopf AC, Hong TS, Lomax A. Scanned proton radiotherapy for mobile targets—the effectiveness of re-scanning in the context of different treatment planning approaches and for different motion characteristics. *Phys Med Biol*. 2011;56:7257–7271.

28. Li Y, Kardar L, Li X, et al On the interplay effects with proton scanning beams in stage III lung cancer. *Med Phys*. 2014;41:021721.

29. Liu C, Sio TT, Deng W, et al Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: a dosimetric comparative study. *J Appl Clin Med Phys*. 2018;19:140–148.

30. Castillo R, Castillo E, Martinez J, Guerrero T. Ventilation from four-dimensional computed tomography: density versus Jacobian methods. *Phys Med Biol*. 2010;55:4661–4685.

31. Castillo E. Quadratic penalty method for intensity-based deformable image registration and 4DCT lung motion recovery. *Med Phys*. 2019;46:2194–2203.

32. Bayouth J, Du K, Christensen G, Smith B, Buatti J, Reinhardt J. Establishing a relationship between radiosensitivity of lung tissue and ventilation. *Int J Radiat Oncol Biol Phys*. 2012;84:531–532.

33. Yamamoto T, Kabus S, von Berg J, Lorenz C, Keall PJ. Impact of four-dimensional computed tomography pulmonary ventilation imaging-based functional avoidance for lung cancer radiotherapy. *Int J Radiat Oncol Biol Phys*. 2011;79:279–288.

34. Waxweiler T, Schubert L, Diot Q, et al A complete 4DCT-ventilation functional avoidance virtual trial: developing strategies for prospective clinical trials. *J Appl Clin Med Phys*. 2017;18:144–152.

35. Zenklusen SM, Pedroni E, Meer D. A study on repaintaging strategies for treating moderately moving targets with proton pencil beam scanning at the new Gantry 2 at PSI. *Phys Med Biol*. 2010;55:5103–5121.

36. Chan Tseung H, Ma J, Beltran C. A fast GPU-based Monte Carlo simulation of proton transport with detailed modeling of nonelastic interactions. *Med Phys*. 2015;42:2967–2978.

37. Shen J, Tryggestad E, Younkin JE, et al Technical Note: using experimentally determined proton spot scanning timing parameters to accurately model beam delivery time. *Med Phys*. 2017;44:5081–5088.

38. Pepin MD, Tryggestad E, Chan Tseung H, Johnson JE, Herman MG, Beltran C. A Monte-Carlo-based and GPU-accelerated 4D-dose calculator for a pencil beam scanning proton therapy system. *Med Phys*. 2018;45:5293–5304.

39. Faught AM, Miyasaka Y, Kadoya N, et al Evaluating the toxicity reduction with computed tomographic ventilation functional avoidance radiation therapy. *Int J Radiat Oncol Biol Phys*. 2017;99:325–333.

40. Faught AM, Yamamoto T, Castillo R, et al Evaluating which dose-function metrics are most critical for functional-guided radiation therapy. *Int J Radiat Oncol Biol Phys*. 2017;99:202–209.

41. Huang Q, Jabbour SK, Xiao Z, et al Dosimetric feasibility of 4DCT-ventilation imaging guided proton therapy for locally advanced non-small-cell lung cancer. *Radiat Oncol*. 2018;13:78.

42. Chang JY, Zhang X, Knopf A, et al Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee. *Int J Radiat Oncol Biol Phys*. 2017;99:41–50.

43. Gelover E, Deisher AJ, Herman MG, Johnson JE, Kruse JJ, Tryggestad EJ. Clinical implementation of respiratory-gated spot-scanning proton therapy: an efficacy analysis of active motion management. *J Appl Clin Med Phys*. 2019;20:99–108.
### Table A1
Normal Tissue Complication Probability values for grade 3+ radiation pneumonitis are shown here for the functional lung volume metrics for the standard and functional plans in both the proton and photon modalities

| Grade 3+ toxicity | Dose metric for NTCP | Toxicity probability of the mean—VMAT standard | Toxicity probability of the mean—VMAT functional | Absolute reduction [range of reduction] |
|-------------------|----------------------|-----------------------------------------------|-------------------------------------------------|----------------------------------------|
|                   | fV20 Gy (Gy)         | 15.5% (2.9%–40.4%)                            | 12.1% (2.7%–34.2%)                              | 3.4% (−0.1%–8.1%)                      |
|                   | fV30 Gy (Gy)         | 11.3% (3.6%–27.8%)                            | 9.7% (3.4%–24.7%)                               | 1.6% (0%–4.4%)                        |
|                   | fVMLD (Gy)           | 11.1% (4.9%–16.4%)                            | 9.8% (4.7%–15.3%)                               | 1.3% (0%–3%)                          |
|                   | fV20 Gy (Gy)         | 8.4% (2.2%–27.7%)                             | 6% (2%–18.1%)                                   | 2.4% (0%–15.4%)                       |
|                   | fV30 Gy (Gy)         | 8.4% (3.1%–25.9%)                             | 6.7% (2.9%–18%)                                 | 1.7% (0%–10.2%)                       |
|                   | fVMLD (Gy)           | 6.2% (3.1%–11.8%)                             | 5.4% (2.9%–9.6%)                                | 0.8% (0%–3.2%)                        |

### Table B1
DVH dose metrics comparisons between non-dose-escalated and dose-escalated IMPT plans (n = 22)

| CTV metrics | Intensity modulated proton—standard | P value | Intensity modulated proton—functional | P value |
|-------------|-------------------------------------|---------|--------------------------------------|---------|
|             | Nondose-escalated plan | Dose-escalated Plan | | Nondose-escalated Plan | Dose-escalated Plan | |
| CTV max (RBE[Gy]) | 63.82 | 74.36 | $<0.00$ | 64.64 | 74.36 | $<0.00$ |
| Total MLD (RBE[Gy]) | 10.71 | 10.97 | 0.37 | 9.72 | 9.97 | 0.43 |
| Total lung V20 (%) | 21.26 | 20.99 | 0.84 | 18.60 | 18.02 | 0.39 |
| Total lung V5 (%) | 30.77 | 30.24 | 0.48 | 28.77 | 28.76 | 0.99 |
| Esophagus mean (RBE[Gy]) | 19.04 | 20.34 | 0.33 | 18.97 | 20.51 | 0.23 |
| Heart mean (RBE[Gy]) | 5.38 | 4.78 | 0.12 | 5.06 | 4.86 | 0.38 |
| Cord max (RBE[Gy]) | 32.56 | 35.06 | 0.23 | 34.38 | 35.93 | 0.37 |

| Functional lung metrics | Ipsilateral | Contralateral | Total lung |
|--------------------------|-------------|---------------|------------|
| MLD (RBE[Gy]) | 21.210 | 1.91 | 10.17 |
| Lung V5 (%) | 60.86 | 8.47 | 31.10 |
| Lung V20 (%) | 42.78 | 3.02 | 27.11 |
| Lung V30 (%) | 33.17 | 1.26 | 10.26 |
| Lung V5 (%) | 58.44 | 4.79 | 29.96 |
| Lung V20 (%) | 41.45 | 2.69 | 25.89 |
| Lung V30 (%) | 32.86 | 1.05 | 19.65 |
| Lung V5 (%) | 17.90 | 0.85 | 0.68 |
| Lung V20 (%) | 55.19 | 0.85 | 0.50 |
| Lung V30 (%) | 34.08 | 0.85 | 0.48 |
| Lung V5 (%) | 26.79 | 1.90 | 8.52 |
| Lung V20 (%) | 53.74 | 1.90 | 8.38 |
| Lung V30 (%) | 31.52 | 1.90 | 0.02 |
| Lung V5 (%) | 24.71 | 1.90 | 0.02 |
| Lung V20 (%) | 53.74 | 1.90 | 0.02 |
| Lung V30 (%) | 31.52 | 1.90 | 0.02 |
| Lung V5 (%) | 24.71 | 1.90 | 0.02 |
| Lung V20 (%) | 53.74 | 1.90 | 0.02 |
| Lung V30 (%) | 31.52 | 1.90 | 0.02 |